Vico Therapeutics B.V. announced that it has received ?54 million ($60 million) in a round of funding co-led by new investor, Ackermans & Van Haaren NV and from returning investors, DROIA nv, EQT Life Sciences and Kurma Partners SA on January 5, 2024. The transaction included participation from returning investors, Polaris Venture Partners, Inc., Pureos Partners AG and Eurazeo Investment Manager. As a part of transaction, Jeroen Vangindertael at Ackermans & Van Haaren NV, will join the company's board of directors.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
160.5 EUR | +1.65% | +1.45% | +1.07% |
Feb. 29 | ACKERMANS & VAN HAAREN : Ackermans signs off a fast year | |
Feb. 29 | ACKERMANS & VAN HAAREN : AvH released solid 2023 figures |
EPS Revisions
Annual profits - Rate of surprise
1st Jan change | Capi. | |
---|---|---|
+1.07% | 5.6B | |
-2.29% | 67.67B | |
+2.13% | 59.37B | |
+21.25% | 38.3B | |
+11.23% | 30.73B | |
+2.06% | 26.35B | |
+22.89% | 22.01B | |
+15.06% | 19.47B | |
+22.99% | 17.6B | |
+64.33% | 16.64B |
- Stock Market
- Equities
- ACKB Stock
- News Ackermans & van Haaren NV
- Vico Therapeutics B.V. announced that it has received ?54 million in funding from a group of investors